• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

原发性膜性肾病的发病机制。

Mechanisms of Primary Membranous Nephropathy.

机构信息

Department of Surgery, McMaster University, Hamilton, ON L8S 4K1, Canada.

Urological Cancer Center for Research and Innovation (UCCRI), St Joseph's Hospital, Hamilton, ON L8N 4A6, Canada.

出版信息

Biomolecules. 2021 Mar 30;11(4):513. doi: 10.3390/biom11040513.

DOI:10.3390/biom11040513
PMID:33808418
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8065962/
Abstract

Membranous nephropathy (MN) is an autoimmune disease of the kidney glomerulus and one of the leading causes of nephrotic syndrome. The disease exhibits heterogenous outcomes with approximately 30% of cases progressing to end-stage renal disease. The clinical management of MN has steadily advanced owing to the identification of autoantibodies to the phospholipase A2 receptor (PLA2R) in 2009 and thrombospondin domain-containing 7A (THSD7A) in 2014 on the podocyte surface. Approximately 50-80% and 3-5% of primary MN (PMN) cases are associated with either anti-PLA2R or anti-THSD7A antibodies, respectively. The presence of these autoantibodies is used for MN diagnosis; antibody levels correlate with disease severity and possess significant biomarker values in monitoring disease progression and treatment response. Importantly, both autoantibodies are causative to MN. Additionally, evidence is emerging that NELL-1 is associated with 5-10% of PMN cases that are PLA2R- and THSD7A-negative, which moves us one step closer to mapping out the full spectrum of PMN antigens. Recent developments suggest exostosin 1 (EXT1), EXT2, NELL-1, and contactin 1 (CNTN1) are associated with MN. Genetic factors and other mechanisms are in place to regulate these factors and may contribute to MN pathogenesis. This review will discuss recent developments over the past 5 years.

摘要

膜性肾病(MN)是一种肾脏肾小球的自身免疫性疾病,也是肾病综合征的主要病因之一。该疾病的临床表现具有异质性,约 30%的病例会进展为终末期肾病。由于在 2009 年发现了足细胞表面的磷脂酶 A2 受体(PLA2R)和 2014 年发现了血小板反应蛋白域包含 7A(THSD7A)自身抗体,MN 的临床治疗得到了稳步推进。大约 50-80%和 3-5%的原发性 MN(PMN)病例分别与抗 PLA2R 或抗 THSD7A 抗体相关。这些自身抗体的存在用于 MN 的诊断;抗体水平与疾病严重程度相关,并在监测疾病进展和治疗反应方面具有重要的生物标志物价值。重要的是,这两种自身抗体都是导致 MN 的原因。此外,有证据表明,NELL-1 与 5-10%的 PLA2R 和 THSD7A 阴性的 PMN 病例有关,这使我们更接近绘制出完整的 PMN 抗原图谱。最近的研究进展表明,外生骨疣 1(EXT1)、EXT2、NELL-1 和接触蛋白 1(CNTN1)与 MN 有关。遗传因素和其他机制可以调节这些因素,并可能导致 MN 的发病机制。本文将讨论过去 5 年来的最新研究进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/8065962/b07dbb258bed/biomolecules-11-00513-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/8065962/d40949fe752b/biomolecules-11-00513-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/8065962/b07dbb258bed/biomolecules-11-00513-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/8065962/d40949fe752b/biomolecules-11-00513-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d29/8065962/b07dbb258bed/biomolecules-11-00513-g002.jpg

相似文献

1
Mechanisms of Primary Membranous Nephropathy.原发性膜性肾病的发病机制。
Biomolecules. 2021 Mar 30;11(4):513. doi: 10.3390/biom11040513.
2
Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.外显素 1/外显素 2 相关的膜性肾病。
J Am Soc Nephrol. 2019 Jun;30(6):1123-1136. doi: 10.1681/ASN.2018080852. Epub 2019 May 6.
3
Clinical significance of Mtype phospholipase A2 receptor and thrombospondin Type 1 domaincontaining 7A in primary membranous nephropathy.M型磷脂酶A2受体和含血小板反应蛋白1结构域7A在原发性膜性肾病中的临床意义
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020 Jun 28;45(6):693-700. doi: 10.11817/j.issn.1672-7347.2020.190109.
4
Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy.中国特发性膜性肾病患者血栓反应蛋白型 I 域包含蛋白 7A 的循环抗体。
Clin J Am Soc Nephrol. 2017 Oct 6;12(10):1642-1651. doi: 10.2215/CJN.01460217. Epub 2017 Aug 11.
5
Primary Membranous Nephropathy.原发性膜性肾病
Clin J Am Soc Nephrol. 2017 Jun 7;12(6):983-997. doi: 10.2215/CJN.11761116. Epub 2017 May 26.
6
PLA2R and THSD7A: Disparate Paths to the Same Disease?磷脂酶A2受体(PLA2R)和血小板反应蛋白基序含7A结构域蛋白(THSD7A):通往同一种疾病的不同途径?
J Am Soc Nephrol. 2017 Sep;28(9):2579-2589. doi: 10.1681/ASN.2017020178. Epub 2017 Jul 3.
7
Circulating antibodies against M-type phospholipase A2 receptor and thrombospondin type-1 domain-containing 7A in Chinese patients with membranous nephropathy.中国膜性肾病患者中针对 M 型磷脂酶 A2 受体和血栓反应素型-1 结构域包含蛋白 7A 的循环抗体。
Int Urol Nephrol. 2019 Aug;51(8):1371-1377. doi: 10.1007/s11255-019-02146-w. Epub 2019 Jun 21.
8
Clinical and Histological Features of Phospholipase A2 Receptor-Associated and Thrombospondin Type-I Domain-containing 7A-Associated Idiopathic Membranous Nephropathy: A Single Center Retrospective Study from China.中国单中心回顾性研究:磷脂酶 A2 受体相关和血栓素型 1 域包含 7A 相关特发性膜性肾病的临床和组织学特征。
Med Sci Monit. 2018 Jul 22;24:5076-5083. doi: 10.12659/MSM.909815.
9
A Target Antigen-Based Approach to the Classification of Membranous Nephropathy.基于靶抗原的膜性肾病分类方法。
Mayo Clin Proc. 2021 Mar;96(3):577-591. doi: 10.1016/j.mayocp.2020.11.028.
10
Membranous nephropathy: integrating basic science into improved clinical management.膜性肾病:将基础科学融入改进的临床管理中。
Kidney Int. 2017 Mar;91(3):566-574. doi: 10.1016/j.kint.2016.09.048. Epub 2017 Jan 5.

引用本文的文献

1
Depletion of myeloid-derived suppressor cells alleviates kidney damage in murine membranous nephropathy.髓源性抑制细胞的消耗可减轻小鼠膜性肾病中的肾脏损伤。
Front Immunol. 2025 Aug 27;16:1623613. doi: 10.3389/fimmu.2025.1623613. eCollection 2025.
2
Integrating bioinformatics and machine learning to elucidate the role of protein glycosylation-related genes in the pathogenesis of diabetic kidney disease.整合生物信息学和机器学习以阐明蛋白质糖基化相关基因在糖尿病肾病发病机制中的作用。
PLoS One. 2025 Aug 18;20(8):e0329640. doi: 10.1371/journal.pone.0329640. eCollection 2025.
3
Case Report: Subcutaneous ofatumumab for patients with immunosuppressant-dependent or ineffective primary membranous nephropathy.

本文引用的文献

1
New 'Antigens' in Membranous Nephropathy.膜性肾病中的新“抗原”。
J Am Soc Nephrol. 2021 Feb;32(2):268-278. doi: 10.1681/ASN.2020071082. Epub 2020 Dec 30.
2
Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy.IgG4 糖基化改变促进抗 PLA2R1 相关膜性肾病中凝集素补体途径的激活。
J Clin Invest. 2021 Mar 1;131(5). doi: 10.1172/JCI140453.
3
Therapeutic targeting of the oncogenic Wnt signaling pathway for treating colorectal cancer and other colonic disorders.
病例报告:皮下注射奥法木单抗治疗免疫抑制剂依赖型或无效的原发性膜性肾病患者。
Front Immunol. 2025 Jun 30;16:1610530. doi: 10.3389/fimmu.2025.1610530. eCollection 2025.
4
Prognostic Factors of Proteinuria Remission in Primary Membranous Nephropathy.原发性膜性肾病蛋白尿缓解的预后因素
J Clin Med. 2025 Apr 22;14(9):2880. doi: 10.3390/jcm14092880.
5
Telitacicept and Tacrolimus Synergy in Managing Refractory Primary Membranous Nephropathy: Case Insights.泰它西普与他克莫司联合治疗难治性原发性膜性肾病:病例分析
Am J Case Rep. 2025 Apr 23;26:e946727. doi: 10.12659/AJCR.946727.
6
Membranous Nephropathy Target Antigens Display Podocyte-Specific and Non-Specific Expression in Healthy Kidneys.膜性肾病靶抗原在健康肾脏中呈现足细胞特异性和非特异性表达。
Genes (Basel). 2025 Feb 20;16(3):241. doi: 10.3390/genes16030241.
7
Role of PLA2R domain antibodies and epitope spreading in risk stratification and prediction of proteinuria remission in primary membranous nephropathy.磷脂酶A2受体结构域抗体及表位扩展在原发性膜性肾病蛋白尿缓解的风险分层及预测中的作用
Sci Rep. 2025 Feb 26;15(1):6868. doi: 10.1038/s41598-025-91366-5.
8
Family study of bipolar disorder with comorbid anxiety disorder points to with possible role of parent-of-origin effect.双相情感障碍合并焦虑症的家系研究指出了可能存在的源自父母的效应的作用。
PCN Rep. 2025 Feb 19;4(1):e70071. doi: 10.1002/pcn5.70071. eCollection 2025 Mar.
9
Neutrophil extracellular traps potentiate effector T cells via endothelial senescence in uveitis.中性粒细胞胞外诱捕网通过葡萄膜炎中的内皮细胞衰老增强效应T细胞。
JCI Insight. 2025 Jan 23;10(2):e180248. doi: 10.1172/jci.insight.180248.
10
Screening potential diagnostic biomarkers for PLA2R‑associated idiopathic membranous nephropathy by WGCNA analysis and LASSO algorithm.通过加权基因共表达网络分析(WGCNA)和套索(LASSO)算法筛选与磷脂酶A2受体(PLA2R)相关的特发性膜性肾病的潜在诊断生物标志物。
Ren Fail. 2025 Dec;47(1):2438859. doi: 10.1080/0886022X.2024.2438859. Epub 2025 Jan 13.
针对致癌性 Wnt 信号通路的治疗靶向治疗用于治疗结直肠癌和其他结肠疾病。
Adv Drug Deliv Rev. 2021 Feb;169:118-136. doi: 10.1016/j.addr.2020.12.010. Epub 2020 Dec 24.
4
MEK inhibitor resistance mechanisms and recent developments in combination trials.MEK 抑制剂耐药机制及联合试验的最新进展。
Cancer Treat Rev. 2021 Jan;92:102137. doi: 10.1016/j.ctrv.2020.102137. Epub 2020 Dec 16.
5
Multi-Autoantibody Signature and Clinical Outcome in Membranous Nephropathy.多自身抗体特征与膜性肾病的临床结局。
Clin J Am Soc Nephrol. 2020 Dec 7;15(12):1762-1776. doi: 10.2215/CJN.02500220. Epub 2020 Nov 30.
6
Renal expression of PLA2R, THSD7A, and IgG4 in patients with membranous nephropathy and correlation with clinical findings.膜性肾病患者肾组织中 PLA2R、THSD7A 和 IgG4 的表达及其与临床特征的相关性。
Int J Clin Pract. 2021 Apr;75(4):e13855. doi: 10.1111/ijcp.13855. Epub 2020 Dec 13.
7
The Role of Contactin 1 in Cancers: What We Know So Far.Contactin 1在癌症中的作用:我们目前所了解的情况。
Front Oncol. 2020 Oct 29;10:574208. doi: 10.3389/fonc.2020.574208. eCollection 2020.
8
Meta-Analysis of the Diagnostic Efficiency of THSD7A-AB for the Diagnosis of Idiopathic Membranous Nephropathy.THSD7A抗体对特发性膜性肾病诊断效能的Meta分析
Glob Chall. 2020 Sep 6;4(11):1900099. doi: 10.1002/gch2.201900099. eCollection 2020 Nov.
9
Is primary membranous nephropathy a complement mediated disease?原发性膜性肾病是否为补体介导的疾病?
Mol Immunol. 2020 Dec;128:195-204. doi: 10.1016/j.molimm.2020.10.017. Epub 2020 Nov 1.
10
A Comprehensive Phenotypic and Functional Immune Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in Membranous Nephropathy Patients.一项全面的表型和功能免疫分析揭示了膜性肾病患者循环中分泌抗磷脂酶A2受体抗体的细胞。
Kidney Int Rep. 2020 Aug 1;5(10):1764-1776. doi: 10.1016/j.ekir.2020.07.028. eCollection 2020 Oct.